25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ZVAA (Cellectis) Stock Analysis
Buy, Hold or Sell?

Let's analyze Cellectis together

I guess you are interested in Cellectis S.A. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Cellectis’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Cellectis’s Price Targets

I'm going to help you getting a better view of Cellectis S.A. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Cellectis S.A

I send you an email if I find something interesting about Cellectis S.A.

1. Quick Overview

1.1. Quick analysis of Cellectis (30 sec.)










1.2. What can you expect buying and holding a share of Cellectis? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€1.15
Expected worth in 1 year
€1.56
How sure are you?
31.8%

+ What do you gain per year?

Total Gains per Share
€0.41
Return On Investment
32.1%

For what price can you sell your share?

Current Price per Share
€1.27
Expected price per share
€0.905 - €1.56
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Cellectis (5 min.)




Live pricePrice per Share (EOD)
€1.27
Intrinsic Value Per Share
€6.07 - €7.43
Total Value Per Share
€7.22 - €8.59

2.2. Growth of Cellectis (5 min.)




Is Cellectis growing?

Current yearPrevious yearGrowGrow %
How rich?$131m$94.4m$30.4m24.4%

How much money is Cellectis making?

Current yearPrevious yearGrowGrow %
Making money-$9.1m-$25.2m$16m174.9%
Net Profit Margin-71.2%-13,510.6%--

How much money comes from the company's main activities?

2.3. Financial Health of Cellectis (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#318 / 908

Most Revenue
#288 / 908

Most Profit
#476 / 908

Most Efficient
#487 / 908
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Cellectis?

Welcome investor! Cellectis's management wants to use your money to grow the business. In return you get a share of Cellectis.

First you should know what it really means to hold a share of Cellectis. And how you can make/lose money.

Speculation

The Price per Share of Cellectis is €1.27. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cellectis.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cellectis, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €1.15. Based on the TTM, the Book Value Change Per Share is €0.10 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.09 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cellectis.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 β‚¬% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share
Usd Eps0.064.7%-0.09-7.2%-0.20-16.1%-0.21-16.5%-0.22-17.0%
Usd Book Value Change Per Share0.021.3%0.129.1%-0.10-8.1%-0.11-8.8%0.064.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.021.3%0.129.1%-0.10-8.1%-0.11-8.8%0.064.7%
Usd Price Per Share1.51-2.08-2.19-7.66-8.27-
Price to Earnings Ratio6.37-3.61--3.32--5.39--6.21-
Price-to-Total Gains Ratio93.83-33.20--3.41--11.10--13.13-
Price to Book Ratio1.15-1.79-2.40-3.25-3.31-
Price-to-Total Gains Ratio93.83-33.20--3.41--11.10--13.13-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.44018
Number of shares694
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.12-0.11
Usd Total Gains Per Share0.12-0.11
Gains per Quarter (694 shares)80.32-77.80
Gains per Year (694 shares)321.27-311.21
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
103213110-311-321
206436320-622-632
309649530-934-943
40128512740-1245-1254
50160615950-1556-1565
60192819160-1867-1876
70224922370-2178-2187
80257025580-2490-2498
90289128790-2801-2809
100321332000-3112-3120

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%2.010.00.016.7%3.017.00.015.0%3.019.00.013.6%3.019.00.013.6%
Book Value Change Per Share3.01.00.075.0%4.08.00.033.3%6.014.00.030.0%7.015.00.031.8%7.015.00.031.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.022.00.0%0.00.022.00.0%
Total Gains per Share3.01.00.075.0%4.08.00.033.3%6.014.00.030.0%7.015.00.031.8%7.015.00.031.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Cellectis S.A compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0140.102-86%-0.091+741%-0.099+797%0.052-73%
Book Value Per Share--1.1541.100+5%0.832+39%1.750-34%1.887-39%
Current Ratio--1.7271.762-2%2.166-20%3.728-54%4.036-57%
Debt To Asset Ratio--0.6580.678-3%0.620+6%0.481+37%0.458+44%
Debt To Equity Ratio--1.9272.160-11%1.803+7%1.192+62%1.113+73%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value---89539179.800-45902596.850-49%51450415.850-274%526662825.300-117%585902100.027-115%
Eps--0.052-0.081+255%-0.180+445%-0.185+455%-0.190+464%
Ev To Ebitda Ratio--infnannan%infnan%nannan%nannan%
Ev To Sales Ratio---1.996-1.063-47%79.504-103%43.451-105%45.179-104%
Free Cash Flow Per Share---0.0160.042-137%-0.053+237%-0.152+865%-0.152+865%
Free Cash Flow To Equity Per Share--0.0100.238-96%0.129-92%-0.032+422%-0.032+422%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--7.433--------
Intrinsic Value_10Y_min--6.067--------
Intrinsic Value_1Y_max---0.131--------
Intrinsic Value_1Y_min---0.129--------
Intrinsic Value_3Y_max--0.274--------
Intrinsic Value_3Y_min--0.249--------
Intrinsic Value_5Y_max--1.484--------
Intrinsic Value_5Y_min--1.320--------
Market Cap127119380.000-5%133125020.000183672490.000-28%193681890.000-31%676235064.000-80%730322221.818-82%
Net Profit Margin--0.466-0.712+253%-135.106+29113%-36.865+8016%-33.983+7398%
Operating Margin----0%-33.2280%-18.0550%-16.9540%
Operating Ratio--1.8403.064-40%136.957-99%40.517-95%37.545-95%
Pb Ratio1.100-5%1.1521.789-36%2.404-52%3.247-65%3.311-65%
Pe Ratio6.086-5%6.3733.607+77%-3.325+152%-5.392+185%-6.207+197%
Price Per Share1.270-5%1.3301.835-28%1.935-31%6.756-80%7.296-82%
Price To Free Cash Flow Ratio-20.111+5%-21.062-7.836-63%-1.154-95%-14.508-31%-13.189-37%
Price To Total Gains Ratio89.595-5%93.82833.198+183%-3.411+104%-11.103+112%-13.127+114%
Quick Ratio--0.7440.632+18%0.273+173%0.618+20%0.613+21%
Return On Assets--0.015-0.022+244%-0.094+712%-0.063+509%-0.063+505%
Return On Equity--0.045-0.060+233%-0.278+714%-0.141+411%-0.135+400%
Total Gains Per Share--0.0140.102-86%-0.091+741%-0.099+797%0.052-73%
Usd Book Value--131027915.920124903403.560+5%94462584.710+39%198693090.409-34%214139736.510-39%
Usd Book Value Change Per Share--0.0160.116-86%-0.103+741%-0.112+797%0.060-73%
Usd Book Value Per Share--1.3091.248+5%0.944+39%1.985-34%2.139-39%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value---101537429.893-52053544.828-49%58344771.574-274%597235643.890-117%664412981.431-115%
Usd Eps--0.059-0.092+255%-0.204+445%-0.210+455%-0.215+464%
Usd Free Cash Flow---1791930.4704786314.284-137%-6044015.483+237%-17286479.259+865%-15714981.144+777%
Usd Free Cash Flow Per Share---0.0180.048-137%-0.060+237%-0.173+865%-0.173+865%
Usd Free Cash Flow To Equity Per Share--0.0110.270-96%0.147-92%-0.036+422%-0.036+422%
Usd Market Cap144153376.920-5%150963772.680208284603.660-28%219635263.260-31%766850562.576-80%828185399.542-82%
Usd Price Per Share1.440-5%1.5082.081-28%2.194-31%7.661-80%8.274-82%
Usd Profit--5921770.226-9189893.418+255%-25265519.660+527%-21959047.956+471%-22389358.532+478%
Usd Revenue--12716506.58010376097.392+23%188742.677+6637%9640925.918+32%9351818.954+36%
Usd Total Gains Per Share--0.0160.116-86%-0.103+741%-0.112+797%0.060-73%
 EOD+3 -5MRQTTM+18 -17YOY+23 -125Y+22 -1310Y+18 -17

3.3 Fundamental Score

Let's check the fundamental score of Cellectis S.A based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-156.086
Price to Book Ratio (EOD)Between0-11.100
Net Profit Margin (MRQ)Greater than00.466
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.744
Current Ratio (MRQ)Greater than11.727
Debt to Asset Ratio (MRQ)Less than10.658
Debt to Equity Ratio (MRQ)Less than11.927
Return on Equity (MRQ)Greater than0.150.045
Return on Assets (MRQ)Greater than0.050.015
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Cellectis S.A based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5060.725
Ma 20Greater thanMa 501.095
Ma 50Greater thanMa 1001.235
Ma 100Greater thanMa 2001.437
OpenGreater thanClose1.270
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Cellectis S.A

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Fundamental data was last updated by Penke on 2025-04-10 23:34:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is cheap.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Cellectis earns for each €1 of revenue.

  • Above 10% is considered healthy but always compareΒ Cellectis to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 46.6%Β means thatΒ €0.47 for each €1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cellectis S.A:

  • The MRQ is 46.6%. The company is making a huge profit. +2
  • The TTM is -71.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ46.6%TTM-71.2%+117.7%
TTM-71.2%YOY-13,510.6%+13,439.4%
TTM-71.2%5Y-3,686.5%+3,615.4%
5Y-3,686.5%10Y-3,398.3%-288.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ46.6%-99.7%+146.3%
TTM-71.2%-188.1%+116.9%
YOY-13,510.6%-199.6%-13,311.0%
5Y-3,686.5%-357.6%-3,328.9%
10Y-3,398.3%-488.5%-2,909.8%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Cellectis is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Cellectis to theΒ Biotechnology industry mean.
  • 1.5% Return on Assets means thatΒ Cellectis generatedΒ €0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cellectis S.A:

  • The MRQ is 1.5%. Using its assets, the company is less efficient in making profit.
  • The TTM is -2.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ1.5%TTM-2.2%+3.8%
TTM-2.2%YOY-9.4%+7.2%
TTM-2.2%5Y-6.3%+4.1%
5Y-6.3%10Y-6.3%-0.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5%-12.3%+13.8%
TTM-2.2%-12.2%+10.0%
YOY-9.4%-12.0%+2.6%
5Y-6.3%-13.4%+7.1%
10Y-6.3%-15.3%+9.0%
4.3.1.3. Return on Equity

Shows how efficient Cellectis is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Cellectis to theΒ Biotechnology industry mean.
  • 4.5% Return on Equity means Cellectis generated €0.05Β for eachΒ €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cellectis S.A:

  • The MRQ is 4.5%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is -6.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ4.5%TTM-6.0%+10.5%
TTM-6.0%YOY-27.8%+21.7%
TTM-6.0%5Y-14.1%+8.1%
5Y-14.1%10Y-13.5%-0.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.5%-16.1%+20.6%
TTM-6.0%-16.2%+10.2%
YOY-27.8%-15.8%-12.0%
5Y-14.1%-19.5%+5.4%
10Y-13.5%-21.7%+8.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Cellectis S.A.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Cellectis is operatingΒ .

  • Measures how much profit Cellectis makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Cellectis to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated €0.00 Β for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cellectis S.A:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-3,322.8%+3,322.8%
TTM-5Y-1,805.5%+1,805.5%
5Y-1,805.5%10Y-1,695.4%-110.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--188.3%+188.3%
TTM--291.0%+291.0%
YOY-3,322.8%-214.8%-3,108.0%
5Y-1,805.5%-368.2%-1,437.3%
10Y-1,695.4%-471.9%-1,223.5%
4.3.2.2. Operating Ratio

Measures how efficient Cellectis is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 1.84 means that the operating costs are €1.84 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Cellectis S.A:

  • The MRQ is 1.840. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.064. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.840TTM3.064-1.224
TTM3.064YOY136.957-133.894
TTM3.0645Y40.517-37.454
5Y40.51710Y37.545+2.973
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8402.233-0.393
TTM3.0643.152-0.088
YOY136.9573.084+133.873
5Y40.5175.091+35.426
10Y37.5456.520+31.025
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Cellectis S.A.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Cellectis is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 1.73Β means the company has €1.73 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Cellectis S.A:

  • The MRQ is 1.727. The company is able to pay all its short-term debts. +1
  • The TTM is 1.762. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.727TTM1.762-0.035
TTM1.762YOY2.166-0.404
TTM1.7625Y3.728-1.966
5Y3.72810Y4.036-0.309
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7273.616-1.889
TTM1.7623.893-2.131
YOY2.1664.280-2.114
5Y3.7285.791-2.063
10Y4.0366.182-2.146
4.4.3.2. Quick Ratio

Measures if Cellectis is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Cellectis to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.74Β means the company can pay off €0.74 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cellectis S.A:

  • The MRQ is 0.744. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.632. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.744TTM0.632+0.112
TTM0.632YOY0.273+0.359
TTM0.6325Y0.618+0.014
5Y0.61810Y0.613+0.005
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7442.920-2.176
TTM0.6323.417-2.785
YOY0.2734.170-3.897
5Y0.6185.727-5.109
10Y0.6136.469-5.856
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Cellectis S.A.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of CellectisΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Cellectis to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.66Β means that Cellectis assets areΒ financed with 65.8% credit (debt) and the remaining percentage (100% - 65.8%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Cellectis S.A:

  • The MRQ is 0.658. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.678. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.658TTM0.678-0.019
TTM0.678YOY0.620+0.058
TTM0.6785Y0.481+0.196
5Y0.48110Y0.458+0.024
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6580.344+0.314
TTM0.6780.344+0.334
YOY0.6200.332+0.288
5Y0.4810.359+0.122
10Y0.4580.384+0.074
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Cellectis is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Cellectis to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 192.7% means that company has €1.93 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cellectis S.A:

  • The MRQ is 1.927. The company is just able to pay all its debts with equity.
  • The TTM is 2.160. The company is just not able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.927TTM2.160-0.233
TTM2.160YOY1.803+0.357
TTM2.1605Y1.192+0.967
5Y1.19210Y1.113+0.079
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9270.407+1.520
TTM2.1600.427+1.733
YOY1.8030.402+1.401
5Y1.1920.448+0.744
10Y1.1130.493+0.620
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every €1 in earnings Cellectis generates.

  • Above 15 is considered overpriced butΒ always compareΒ Cellectis to theΒ Biotechnology industry mean.
  • A PE ratio of 6.37 means the investor is paying €6.37Β for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cellectis S.A:

  • The EOD is 6.086. Based on the earnings, the company is cheap. +2
  • The MRQ is 6.373. Based on the earnings, the company is cheap. +2
  • The TTM is 3.607. Based on the earnings, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD6.086MRQ6.373-0.288
MRQ6.373TTM3.607+2.767
TTM3.607YOY-3.325+6.931
TTM3.6075Y-5.392+8.999
5Y-5.39210Y-6.207+0.815
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD6.086-1.809+7.895
MRQ6.373-2.564+8.937
TTM3.607-3.191+6.798
YOY-3.325-3.323-0.002
5Y-5.392-6.424+1.032
10Y-6.207-7.149+0.942
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cellectis S.A:

  • The EOD is -20.111. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -21.062. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -7.836. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-20.111MRQ-21.062+0.950
MRQ-21.062TTM-7.836-13.225
TTM-7.836YOY-1.154-6.683
TTM-7.8365Y-14.508+6.671
5Y-14.50810Y-13.189-1.319
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-20.111-2.461-17.650
MRQ-21.062-3.566-17.496
TTM-7.836-3.951-3.885
YOY-1.154-4.482+3.328
5Y-14.508-8.693-5.815
10Y-13.189-9.796-3.393
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Cellectis is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 1.15 means the investor is paying €1.15Β for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Cellectis S.A:

  • The EOD is 1.100. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.152. Based on the equity, the company is underpriced. +1
  • The TTM is 1.789. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.100MRQ1.152-0.052
MRQ1.152TTM1.789-0.637
TTM1.789YOY2.404-0.615
TTM1.7895Y3.247-1.458
5Y3.24710Y3.311-0.064
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.1001.676-0.576
MRQ1.1522.283-1.131
TTM1.7892.457-0.668
YOY2.4042.507-0.103
5Y3.2473.773-0.526
10Y3.3114.321-1.010
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets383,544
Total Liabilities252,511
Total Stockholder Equity131,033
 As reported
Total Liabilities 252,511
Total Stockholder Equity+ 131,033
Total Assets = 383,544

Assets

Total Assets383,544
Total Current Assets287,069
Long-term Assets96,476
Total Current Assets
Cash And Cash Equivalents 143,251
Short-term Investments 117,055
Net Receivables 6,714
Other Current Assets 298
Total Current Assets  (as reported)287,069
Total Current Assets  (calculated)267,318
+/- 19,751
Long-term Assets
Property Plant Equipment 75,863
Long Term Investments 7,521
Intangible Assets 1,115
Long-term Assets Other 11,595
Long-term Assets  (as reported)96,476
Long-term Assets  (calculated)96,094
+/- 382

Liabilities & Shareholders' Equity

Total Current Liabilities166,269
Long-term Liabilities86,242
Total Stockholder Equity131,033
Total Current Liabilities
Short Long Term Debt 4,841
Accounts payable 18,664
Other Current Liabilities 12,544
Total Current Liabilities  (as reported)166,269
Total Current Liabilities  (calculated)36,049
+/- 130,220
Long-term Liabilities
Long term Debt 43,990
Capital Lease Obligations Min Short Term Debt42,630
Long-term Liabilities Other 882
Long-term Liabilities  (as reported)86,242
Long-term Liabilities  (calculated)87,502
+/- 1,260
Total Stockholder Equity
Total Stockholder Equity (as reported)131,033
Total Stockholder Equity (calculated)0
+/- 131,033
Other
Capital Stock5,889
Common Stock Shares Outstanding 100,094
Net Invested Capital 179,864
Net Working Capital 120,800
Property Plant and Equipment Gross 167,244



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
> Total Assets 
480,475
467,469
471,135
472,696
484,957
469,471
442,712
457,565
412,886
382,076
347,191
320,883
279,580
261,216
251,408
227,674
209,700
334,270
354,459
407,147
395,876
383,544
383,544395,876407,147354,459334,270209,700227,674251,408261,216279,580320,883347,191382,076412,886457,565442,712469,471484,957472,696471,135467,469480,475
   > Total Current Assets 
410,734
391,520
377,931
347,927
345,718
315,362
272,387
280,352
235,849
225,429
195,175
175,167
140,272
143,810
137,365
113,285
96,495
233,006
258,145
305,738
294,372
287,069
287,069294,372305,738258,145233,00696,495113,285137,365143,810140,272175,167195,175225,429235,849280,352272,387315,362345,718347,927377,931391,520410,734
       Cash And Cash Equivalents 
342,485
340,522
287,133
260,710
302,184
241,148
207,457
248,226
210,709
185,636
154,868
129,440
119,008
97,697
83,515
85,505
67,358
136,708
122,971
149,042
159,087
143,251
143,251159,087149,042122,971136,70867,35885,50583,51597,697119,008129,440154,868185,636210,709248,226207,457241,148302,184260,710287,133340,522342,485
       Short-term Investments 
20,381
20,385
59,005
50,378
41,242
27,091
18,438
3,393
393
499
0
0
21,359
7,907
4,647
1,120
0
67,107
26,200
123,700
101,800
117,055
117,055101,800123,70026,20067,10701,1204,6477,90721,359004993933,39318,43827,09141,24250,37859,00520,38520,381
       Net Receivables 
8,038
15,293
17,865
12,825
12,400
19,194
21,426
11,949
10,231
31,073
33,760
15,532
14,659
25,481
1,120
22,092
393
569
16,036
9,741
11,180
6,714
6,71411,1809,74116,03656939322,0921,12025,48114,65915,53233,76031,07310,23111,94921,42619,19412,40012,82517,86515,2938,038
       Inventory 
3,344
2,897
3,591
5,710
6,262
1,606
5,315
2,468
1,674
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000001,6742,4685,3151,6066,2625,7103,5912,8973,344
       Other Current Assets 
15,321
20,979
21,434
27,001
45,273
27,610
21,922
4,278
832
549
351
670
1,340
22,306
373
828
258
345
274
737
286
298
29828673727434525882837322,3061,3406703515498324,27821,92227,61045,27327,00121,43420,97915,321
   > Long-term Assets 
69,740
75,949
93,204
124,769
139,239
154,109
170,325
177,214
177,037
156,647
152,016
145,716
139,307
117,406
114,042
114,389
113,205
101,265
96,386
101,344
101,445
96,476
96,476101,445101,34496,386101,265113,205114,389114,042117,406139,307145,716152,016156,647177,037177,214170,325154,109139,239124,76993,20475,94969,740
       Property Plant Equipment 
63,153
69,324
84,625
116,322
128,384
145,518
146,616
153,528
152,441
148,269
143,750
135,039
128,871
107,896
105,143
100,688
95,919
92,741
87,840
84,041
81,180
75,863
75,86381,18084,04187,84092,74195,919100,688105,143107,896128,871135,039143,750148,269152,441153,528146,616145,518128,384116,32284,62569,32463,153
       Long Term Investments 
5,468
5,517
7,484
7,376
9,781
7,007
22,105
22,101
22,045
6,524
6,567
9,093
8,926
8,791
8,185
13,006
11,184
7,853
2,315
2,242
2,169
7,521
7,5212,1692,2422,3157,85311,18413,0068,1858,7918,9269,0936,5676,52422,04522,10122,1057,0079,7817,3767,4845,5175,468
       Intangible Assets 
1,120
1,108
1,094
1,071
1,074
1,585
1,604
0
0
1,853
0
0
0
718
0
0
0
672
0
0
0
1,115
1,1150006720007180001,853001,6041,5851,0741,0711,0941,1081,120
       Long-term Assets Other 
1
0
1
-1
0
-1
1
1
1
3
-1
0
-1
1
1
0
4,656
-1
4,655
4,657
4,556
11,595
11,5954,5564,6574,655-14,656011-10-13111-10-1101
> Total Liabilities 
98,704
111,999
100,548
127,637
158,747
160,625
152,968
155,242
150,739
145,602
144,137
140,362
133,968
135,275
130,919
131,116
133,577
249,575
263,893
258,537
266,452
252,511
252,511266,452258,537263,893249,575133,577131,116130,919135,275133,968140,362144,137145,602150,739155,242152,968160,625158,747127,637100,548111,99998,704
   > Total Current Liabilities 
51,381
62,604
49,008
53,052
56,613
52,015
46,922
51,446
49,603
49,348
52,337
55,282
53,030
62,995
60,468
42,047
43,954
155,144
158,446
159,633
165,651
166,269
166,269165,651159,633158,446155,14443,95442,04760,46862,99553,03055,28252,33749,34849,60351,44646,92252,01556,61353,05249,00862,60451,381
       Short Long Term Debt 
2,996
1,067
1,342
0
4,331
0
0
0
0
2,246
3,485
4,841
10,379
5,088
5,068
5,185
4,934
5,162
5,045
4,988
5,217
4,841
4,8415,2174,9885,0455,1624,9345,1855,0685,08810,3794,8413,4852,24600004,33101,3421,0672,996
       Accounts payable 
19,761
29,264
26,873
32,674
35,003
24,609
24,682
28,254
22,809
23,762
20,921
24,159
22,353
21,456
22,324
19,229
20,476
19,069
16,051
18,213
18,511
18,664
18,66418,51118,21316,05119,06920,47619,22922,32421,45622,35324,15920,92123,76222,80928,25424,68224,60935,00332,67426,87329,26419,761
       Other Current Liabilities 
852
24,848
9,743
8,223
7,745
20,710
5,599
5,735
7,648
2,457
11,350
8,496
7,532
16,216
17,908
2,359
1,254
978
1,580
1,177
1,465
12,544
12,5441,4651,1771,5809781,2542,35917,90816,2167,5328,49611,3502,4577,6485,7355,59920,7107,7458,2239,74324,848852
   > Long-term Liabilities 
47,323
49,395
51,540
74,585
102,134
108,610
106,046
103,796
101,136
96,254
91,800
85,080
80,938
72,280
70,451
89,069
89,623
94,431
105,447
98,904
100,801
86,242
86,242100,80198,904105,44794,43189,62389,06970,45172,28080,93885,08091,80096,254101,136103,796106,046108,610102,13474,58551,54049,39547,323
       Capital Lease Obligations Min Short Term Debt
47,462
47,607
50,041
68,641
103,161
82,460
80,383
83,454
81,809
79,855
78,147
74,682
71,563
57,230
56,466
54,427
52,019
51,450
48,991
46,719
45,191
42,630
42,63045,19146,71948,99151,45052,01954,42756,46657,23071,56374,68278,14779,85581,80983,45480,38382,460103,16168,64150,04147,60747,462
       Long-term Liabilities Other 
0
0
0
1
1
4,617
5,778
2,286
2,075
1,885
1,231
1,204
1
1
7,047
1
12,426
12,884
12,596
12,448
12,938
882
88212,93812,44812,59612,88412,42617,047111,2041,2311,8852,0752,2865,7784,61711000
> Total Stockholder Equity
340,636
315,123
331,843
307,606
290,369
275,573
261,926
275,865
237,967
221,293
191,044
168,933
136,641
117,968
113,735
96,558
76,123
84,695
90,566
148,610
129,424
131,033
131,033129,424148,61090,56684,69576,12396,558113,735117,968136,641168,933191,044221,293237,967275,865261,926275,573290,369307,606331,843315,123340,636
   Common Stock
2,766
2,767
2,767
2,768
2,768
2,785
2,801
2,947
2,946
2,945
2,945
2,946
2,949
2,955
0
3,491
0
0
0
0
0
0
0000003,49102,9552,9492,9462,9452,9452,9462,9472,8012,7852,7682,7682,7672,7672,766
   Retained Earnings Total Equity0000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000
   Capital Surplus 0000000000000000000000
   Treasury Stock0000000000000000000000
   Other Stockholders Equity 000000-37,0500-28,605-35,434-29,627-21,261-18,022-14,345-9,602-12,364-4,089-13,556-23,730-29,254-22,641-30,517



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue41,506
Cost of Revenue-0
Gross Profit41,50641,506
 
Operating Income (+$)
Gross Profit41,506
Operating Expense-101,060
Operating Income-59,554-59,554
 
Operating Expense (+$)
Research Development90,536
Selling General Administrative17,602
Selling And Marketing Expenses-
Operating Expense101,060108,138
 
Net Interest Income (+$)
Interest Income11,278
Interest Expense-7,453
Other Finance Cost-0
Net Interest Income3,825
 
Pretax Income (+$)
Operating Income-59,554
Net Interest Income3,825
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-36,761-78,522
EBIT - interestExpense = -7,453
-36,761
-29,308
Interest Expense7,453
Earnings Before Interest and Taxes (EBIT)--29,308
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-36,761
Tax Provision-0
Net Income From Continuing Ops-36,761-36,761
Net Income-36,761
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net18,968-3,825
 

Technical Analysis of Cellectis
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cellectis. The general trend of Cellectis is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cellectis's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Cellectis Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cellectis S.A.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.33 < 1.36 < 1.56.

The bearish price targets are: 1.16 > 0.95 > 0.905.

Know someone who trades $ZVAA? Share this with them.πŸ‘‡

Cellectis S.A Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cellectis S.A. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cellectis S.A Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cellectis S.A. The current macd is -0.02737825.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cellectis price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Cellectis. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Cellectis price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Cellectis S.A Daily Moving Average Convergence/Divergence (MACD) ChartCellectis S.A Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cellectis S.A. The current adx is 22.33.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Cellectis shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Cellectis S.A Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cellectis S.A. The current sar is 1.40405108.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Cellectis S.A Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cellectis S.A. The current rsi is 60.72. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Cellectis S.A Daily Relative Strength Index (RSI) ChartCellectis S.A Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cellectis S.A. The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cellectis price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Cellectis S.A Daily Stochastic Oscillator ChartCellectis S.A Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cellectis S.A. The current cci is 207.70.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Cellectis S.A Daily Commodity Channel Index (CCI) ChartCellectis S.A Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cellectis S.A. The current cmo is 39.24.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Cellectis S.A Daily Chande Momentum Oscillator (CMO) ChartCellectis S.A Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cellectis S.A. The current willr is 0.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Cellectis S.A Daily Williams %R ChartCellectis S.A Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Cellectis S.A.

Cellectis S.A Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cellectis S.A. The current atr is 0.0564545.

Cellectis S.A Daily Average True Range (ATR) ChartCellectis S.A Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cellectis S.A. The current obv is 3,935.

Cellectis S.A Daily On-Balance Volume (OBV) ChartCellectis S.A Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cellectis S.A. The current mfi is 42.66.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Cellectis S.A Daily Money Flow Index (MFI) ChartCellectis S.A Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cellectis S.A.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-11-19 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-20 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-21 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-25 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-26 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-27 00:00:00BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-28 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-29 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-02 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-04 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-05 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-12-06 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-12-11 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-13 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-16 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-17 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-18 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-19 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-20 00:00:00RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-12-23 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-27 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-30 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-02 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-03 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-06 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-07 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-08 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-09 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-10 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-14 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-15 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-01-16 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-01-17 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-21 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-24 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-27 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-28 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-29 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-01-30 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-31 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-03 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-04 00:00:00MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-05 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-06 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-07 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-10 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-13 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-17 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-18 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-19 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-20 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-02-24 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-25 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-26 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-05 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-07 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-10 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-12 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-14 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-03-17 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-18 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-20 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-25 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-26 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-27 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-28 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-07 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-08 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-09 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-14 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-15 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Cellectis S.A Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cellectis S.A based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5060.725
Ma 20Greater thanMa 501.095
Ma 50Greater thanMa 1001.235
Ma 100Greater thanMa 2001.437
OpenGreater thanClose1.270
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Cellectis with someone you think should read this too:
  • Are you bullish or bearish on Cellectis? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cellectis? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cellectis S.A

I send you an email if I find something interesting about Cellectis S.A.


Comments

How you think about this?

Leave a comment

Stay informed about Cellectis S.A.

Receive notifications about Cellectis S.A in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.